Allogene Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Allogene Therapeutics, Inc. (ALLO) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$2.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-12
- Allogene Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $2.28M, a 31.41% increase year-over-year.
- Allogene Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$5.10M.
- Allogene Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$118.00K, a 104.10% decline year-over-year.
- Allogene Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $1.09M, a 57.04% decline year-over-year.
- Allogene Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$2.52M.
- Allogene Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$1.26M.
- Allogene Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$6.82M, a 490.11% decline from fiscal 2022.
- Allogene Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $1.75M, a 52.11% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 1 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$2.82M 10-Q · filed 2026-08-12 | -$2.94M derived: sum of 3 quarters · filed 2026-08-12 | -$1.85M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | -$5.10M 10-Q · filed 2026-05-13 | -$5.22M derived: sum of 2 quarters · filed 2026-05-13 | -$4.13M derived: sum of 3 quarters · filed 2026-05-13 | -$2.40M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | -$118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $968.00K derived: sum of 2 quarters · filed 2026-03-12 | $2.70M derived: sum of 3 quarters · filed 2026-08-12 | -$2.52M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.82M derived: sum of 2 quarters · filed 2026-08-12 | -$2.40M 10-Q · filed 2025-11-06 | $478.00K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $1.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$3.49M 10-Q · filed 2026-08-12 | -$608.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.92M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | -$5.22M 10-Q · filed 2026-05-13 | -$2.34M derived: sum of 2 quarters · filed 2026-05-13 | $185.00K derived: sum of 3 quarters · filed 2026-05-13 | -$795.00K derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.41M derived: sum of 2 quarters · filed 2026-03-12 | $4.43M derived: sum of 3 quarters · filed 2026-03-12 | -$1.26M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.55M derived: sum of 2 quarters · filed 2025-11-06 | -$4.14M 10-Q · filed 2025-11-06 | -$3.86M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | -$980.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$6.67M 10-Q · filed 2025-08-13 | -$6.38M derived: sum of 3 quarters · filed 2025-08-13 | -$19.10M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | -$5.69M 10-Q · filed 2025-05-13 | -$5.40M derived: sum of 2 quarters · filed 2025-05-13 | -$18.12M derived: sum of 3 quarters · filed 2025-05-13 | -$18.20M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $286.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$12.43M derived: sum of 2 quarters · filed 2025-03-13 | -$12.51M derived: sum of 3 quarters · filed 2025-03-13 | -$6.82M 10-K · filed 2025-03-13 | -$6.82M 10-K · filed 2024-03-14 | |||
| 2023-09-30 | -$12.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$12.79M derived: sum of 2 quarters · filed 2024-11-07 | -$7.11M 10-Q · filed 2024-11-07 | -$7.11M 10-Q · filed 2023-11-02 | -$3.97M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-06-30 | -$79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $5.61M 10-Q · filed 2024-08-07 | $5.61M 10-Q · filed 2023-08-02 | $8.74M derived: sum of 3 quarters · filed 2024-08-07 | $10.69M derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2023-03-31 | $5.69M 10-Q · filed 2024-05-13 | $8.82M derived: sum of 2 quarters · filed 2024-05-13 | $10.77M derived: sum of 3 quarters · filed 2024-05-13 | $16.48M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $3.14M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $5.08M derived: sum of 2 quarters · filed 2024-03-14 | $10.80M derived: sum of 3 quarters · filed 2024-03-14 | $1.75M 10-K/A · filed 2024-03-14 | ||||
| 2022-09-30 | $1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $7.66M derived: sum of 2 quarters · filed 2023-11-02 | -$1.39M 10-Q · filed 2023-11-02 | -$4.16M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-06-30 | $5.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$3.33M 10-Q · filed 2023-08-02 | -$6.10M derived: sum of 3 quarters · filed 2024-03-14 | $2.79M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-03-31 | -$9.05M 10-Q · filed 2023-05-03 | -$11.82M derived: sum of 2 quarters · filed 2024-03-14 | -$2.93M derived: sum of 3 quarters · filed 2024-03-14 | -$1.08M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-12-31 | -$2.77M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $6.12M derived: sum of 2 quarters · filed 2024-03-14 | $7.97M derived: sum of 3 quarters · filed 2024-03-14 | $3.65M 10-K/A · filed 2024-03-14 | ||||
| 2021-09-30 | $8.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $10.73M derived: sum of 2 quarters · filed 2022-11-02 | $6.42M 10-Q · filed 2022-11-02 | $8.97M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$2.47M 10-Q · filed 2022-08-09 | $81.00K derived: sum of 3 quarters · filed 2024-03-14 | $9.43M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-03-31 | -$4.31M 10-Q · filed 2022-05-04 | -$1.76M derived: sum of 2 quarters · filed 2024-03-14 | $7.58M derived: sum of 3 quarters · filed 2024-03-14 | $18.32M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2020-12-31 | $2.55M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $11.90M derived: sum of 2 quarters · filed 2024-03-14 | $22.64M derived: sum of 3 quarters · filed 2024-03-14 | $18.73M 10-K/A · filed 2024-03-14 | ||||
| 2020-09-30 | $9.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $20.09M derived: sum of 2 quarters · filed 2021-11-04 | $16.18M 10-Q · filed 2021-11-04 | $15.02M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-06-30 | $10.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $6.83M 10-Q · filed 2021-08-04 | $5.67M derived: sum of 3 quarters · filed 2022-02-23 | $13.29M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-03-31 | -$3.91M 10-Q · filed 2021-05-05 | -$5.07M derived: sum of 2 quarters · filed 2022-02-23 | $2.54M derived: sum of 3 quarters · filed 2022-02-23 | $6.53M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2019-12-31 | -$1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $6.46M derived: sum of 2 quarters · filed 2022-02-23 | $10.45M derived: sum of 3 quarters · filed 2022-02-23 | $6.35M 10-K · filed 2022-02-23 | ||||
| 2019-09-30 | $7.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $11.61M derived: sum of 2 quarters · filed 2020-11-04 | $7.51M 10-Q · filed 2020-11-04 | $6.95M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $3.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$107.00K 10-Q · filed 2020-08-05 | -$664.00K derived: sum of 3 quarters · filed 2021-02-25 | -$553.00K derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | -$4.09M 10-Q · filed 2020-05-06 | -$4.65M derived: sum of 2 quarters · filed 2021-02-25 | -$4.54M derived: sum of 3 quarters · filed 2021-02-25 | $5.45M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | -$557.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$446.00K derived: sum of 2 quarters · filed 2021-02-25 | $9.54M derived: sum of 3 quarters · filed 2021-02-25 | $12.14M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $10.10M derived: sum of 2 quarters · filed 2019-11-05 | $12.70M 10-Q · filed 2019-11-05 | |||||
| 2018-06-30 | $9.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $12.58M 10-Q · filed 2019-08-07 | ||||||
| 2018-03-31 | $2.60M 10-Q · filed 2019-05-07 | |||||||
| 2017-12-31 | $2.00K 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |